Polaris Group’s lead product candidate, ADI-PEG 20 receives US and EU orphan designations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Polaris Group’s lead product candidate, ADI-PEG 20 (pegylated arginine deiminase), received orphan drug designations for the treatment of malignant pleural mesothelioma in the U.S. and the European Union.

Having completed a successful randomized phase II trial in argininosuccinate synthetase -deficient MPM patients with ADI-PEG 20 as monotherapy, Polaris is currently conducting a phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin, the approved first-line treatment for MPM, for the treatment of MPM and non-squamous non-small cell lung carcinoma.

Polaris is also conducting clinical trials on ADI-PEG 20 both as monotherapy and in combination with other agents, for the treatment of several other indications including breast cancer, melanomas, ovarian cancer and hepatocellular carcinoma.

ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login